"Desperate For A Cure: The Search For New Alzheimer's Treatments", a new five-part series by NPR's Sean Corcoran, aired this week on WCAI and will air again next week on WGBH in Boston.
Charlie Collier is a former senior philanthropic advisor for Harvard University and author of the groundbreaking book Wealth in Families. In 2008, at age 60 he was diagnosed with early-onset Alzheimer's disease. Since then, Charlie has devoted himself to speaking out about his condition, and encouraging others to do the same. "I am trying to get people to talk and ask me hard questions," he says.
In a paper just published in the prestigious journal Neuron, Harvard Medical School/Mass General Hospital Geneticist Dr. Rudy Tanzi, together with lead author, Dr. Jaehong Suh and their team, identified two rare mutations in the human gene called "ADAM10" that lead to the most common, late-onset variant of Alzheimer's. Tanzi's research suggests that the ADAM10 gene makes an enzyme called alpha-secretase, which cleaves the Amyloid Precursor Protein (APP) to prevent the formation of beta-amyloid, the toxic protein that triggers brain pathology in Alzheimer's disease.
Drs. Sam Gandy and Scott Noggle have received an NIH grant to gain new insights and identify potential therapies for Alzheimer’s disease.
When author David Shenk wrote The Forgetting, Alzheimer's: Portrait of an Epidemic, he gave us the big picture of Alzheimer's disease. His latest project, "Living With Alzheimer's", a series of four short films created with funding from the MetLife Foundation and in partnership with Cure Alzheimer's Fund, brings us to the personal level.
Cure Alzheimer's Fund congratulates Dr. Thomas Südhof, M.D., a member of our Research Consortium, on winning the Lasker Basic Medical Research Award. The Lasker Award, one of the most respected prizes in medicine, recognizes scientists who have made major contributions to the elimination of some cause of disability or death.
For several years now, researchers have been aware of important links between cholesterol and Alzheimer's disease. A new study by Dr. Dora Kovacs and her team at Massachusetts General Hospital brings us one step closer to a potential drug that could interrupt the disease process.
On May 18 Jeff Morby, chairman and co-founder of Cure Alzheimer’s Fund, was honored with the prestigious Paul Harris Award from Rotary District 7950. Paul Harris founded the Rotary Club more than a century ago and the award was created to recognize those who have made great contributions to society under the Rotary’s motto of “Service Above Self.”
An innovative new public/private collaboration between Cure Alzheimer’s Fund and the National Institute of Mental Health (NIMH) already has started to bear fruit.
SAN DIEGO, July 16, 2013 – Confirming an enzyme in the serine hyrdrolase family as a therapeutic target to slow and potentially reverse the effects of Down syndrome and Alzheimer’s disease is the goal of new research announced today by Abide Therapeutics, in collaboration with researchers at the University of California, San Diego School of Medicine and funded by a grant from the Cure Alzheimer’s Fund.
© 2005-2014 Cure Alzheimer's Fund. All rights reserved.